Mesa Laboratories Inc MLAB
We take great care to ensure that the data presented and summarized in this overview for MESA LABORATORIES INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MLAB
View all-
Black Rock Inc. New York, NY803KShares$109 Million0.0% of portfolio
-
Conestoga Capital Advisors, LLC529KShares$71.6 Million0.95% of portfolio
-
Vanguard Group Inc Valley Forge, PA378KShares$51.1 Million0.0% of portfolio
-
Royce & Associates LP347KShares$47 Million0.43% of portfolio
-
Morgan Stanley New York, NY249KShares$33.8 Million0.0% of portfolio
-
Ranger Investment Management, L.P. Dallas, TX238KShares$32.3 Million2.04% of portfolio
-
State Street Corp Boston, MA214KShares$29 Million0.0% of portfolio
-
Geneva Capital Management LLC192KShares$26 Million0.42% of portfolio
-
Eagle Asset Management Inc St Petersburg, FL166KShares$22.5 Million0.13% of portfolio
-
Atlanta Capital Management CO L L C Atlanta, GA165KShares$22.4 Million0.1% of portfolio
Latest Institutional Activity in MLAB
Top Purchases
Top Sells
About MLAB
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Insider Transactions at MLAB
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 19
2024
|
John James Sullivan Director |
SELL
Bona fide gift
|
Direct |
2,000
-7.17%
|
-
|
Oct 29
2024
|
Gary M Owens President and CEO |
SELL
Open market or private sale
|
Direct |
2,551
-5.56%
|
$283,161
$111.98 P/Share
|
Oct 28
2024
|
Gary M Owens President and CEO |
SELL
Open market or private sale
|
Direct |
2,518
-5.2%
|
$284,534
$113.62 P/Share
|
Oct 27
2024
|
Gary M Owens President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
11,559
+19.28%
|
-
|
Sep 13
2024
|
Brian David Archbold SVP Operations |
SELL
Open market or private sale
|
Direct |
1,499
-100.0%
|
$187,375
$125.0 P/Share
|
Sep 01
2024
|
John Sakys CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
454
-3.63%
|
$60,382
$133.69 P/Share
|
Sep 01
2024
|
John Sakys CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,037
+7.66%
|
-
|
Sep 01
2024
|
Gary M Owens President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,445
-3.77%
|
$192,185
$133.69 P/Share
|
Sep 01
2024
|
Gary M Owens President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,301
+7.94%
|
-
|
Sep 01
2024
|
Brian David Archbold SVP Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
386
-20.48%
|
$51,338
$133.69 P/Share
|
Sep 01
2024
|
Brian David Archbold SVP Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
845
+30.95%
|
-
|
Sep 01
2024
|
John James Sullivan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,074
+3.71%
|
-
|
Sep 01
2024
|
R Tony Tripeny Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,074
+28.62%
|
-
|
Sep 01
2024
|
Shiraz Shabanali Ladiwala Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,574
+33.86%
|
-
|
Sep 01
2024
|
Shannon Hall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,074
+27.83%
|
-
|
Sep 01
2024
|
Jennifer Sadie Alltoft Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,074
+23.61%
|
-
|
Aug 15
2024
|
Mark Christopher Capone Director |
BUY
Exercise of conversion of derivative security
|
Direct |
724
+50.0%
|
-
|
Jun 14
2024
|
Gary M Owens President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,959
+12.41%
|
-
|
Jun 14
2024
|
Brian David Archbold SVP Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
407
-28.13%
|
$37,037
$91.6 P/Share
|
Jun 14
2024
|
Brian David Archbold SVP Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
889
+38.06%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 18.9K shares |
---|---|
Grant, award, or other acquisition | 11.6K shares |
Bona fide gift | 2K shares |
---|---|
Payment of exercise price or tax liability | 3.26K shares |
Open market or private sale | 6.57K shares |